Christy Goldsmith
Research Subjects
Christy Goldsmith has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Timothy Cross
Department of Radiation Oncology, The Harley Street Clinic, London, GBR
2 shared publicationsAmen Sibtain
Department of Radiation Oncology, The Harley Street Clinic, London, GBR
1 shared publicationAndrew Edwards
Department of Radiation Oncology, The Harley Street Clinic, London, GBR
1 shared publicationAndrew Gaya
CyberKnife Centre, The Harley Street Clinic, London, UK; bGuy’s and St. Thomas’ NHS Foundation Trust, London, UK
1 shared publicationHannah P Wilson
Department of Surgery and Cancer, Imperial College London, London, GBR
1 shared publicationIan Cowley
The Harley Street Clinic, London, W1G 8PP, UK
1 shared publication
Latest Publications
- Open Access
- 27 March 2018
- Published by Cureus, Inc. in Cureus
- Vol. 10 (3) , e2380
CyberKnife Radiosurgery of Skull-base Tumors: A UK Center Experience
The study aim was to evaluate patient individualized Cyberknife (R) treatment for heterogeneous skull-base tumors. Patients treated between 2009 and 2013 at The Harley Street Clinic were studied. In total, 66 patients received 15-30 Gy in 1-5 fractions to a median planning target volume (PTV) of 6.4 cc, including patients with secondary, multiple, residual and recurrent tumors, and those with tumors of uncertain pathological type. Outcome analysis was pragmatically restricted to 35 patients who had single, primary tumors treated with curative intent, and sufficient diagnostic and outcome information. Sixteen vestibular schwannoma patients with median PTV 3.8 cc (range 0.81-19.6) received 18-25 Gy in 3-5 fractions: 81% showed no acute toxicity, 50% reported no late toxicity, 71% of symptoms were stable/improved and local control was 100% at 11.4 months median follow-up. Twelve meningioma patients with median PTV of 5.5 cc (range 0.68-22.3) received 17-30 Gy in 1-5 fractions: 83% experienced no acute toxicity, 33% reported no late toxicity, 88% of symptoms were stable/improved and local control was 100% at 22.1 months median follow-up. Seven patients with other tumor types with median PTV of 24.3 cc (range 7.6-100.5) received 15-28.5 Gy in 1-5 fractions: 57% experienced no acute toxicity, 57% reported no late toxicities, 66% of symptoms were stable and local control was 43% at 14.9 months median follow-up. When tumor types were considered together, smaller tumors (PTV < 6.4 cc) showed reduced acute toxicity (p = 0.01). Overall, smaller benign tumors showed low acute toxicity, excellent local control, and good symptom management: a focus on enhanced neurological preservation may refine outcomes. For other tumor types outcome was encouraging: a focus on optimal dose and fractionation scheduling may reduce toxicity and improve local control. Individual patient experiences are detailed where valuable lessons were gained for optimizing local control and minimizing toxicity.
- 27 March 2018
- Published by Cureus, Inc. in Cureus
- Vol. 10 (3) , e2380
Open AccessCyberKnife Radiosurgery of Skull-base Tumors: A UK Center Experience
The study aim was to evaluate patient individualized Cyberknife (R) treatment for heterogeneous skull-base tumors. Patients treated between 2009 and 2013 at The Harley Street Clinic were studied. In total, 66 patients received 15-30 Gy in 1-5 fractions to a median planning target volume (PTV) of 6.4 cc, including patients with secondary, multiple, residual and recurrent tumors, and those with tumors of uncertain pathological type. Outcome analysis was pragmatically restricted to 35 patients who had single, primary tumors treated with curative intent, and sufficient diagnostic and outcome information. Sixteen vestibular schwannoma patients with median PTV 3.8 cc (range 0.81-19.6) received 18-25 Gy in 3-5 fractions: 81% showed no acute toxicity, 50% reported no late toxicity, 71% of symptoms were stable/improved and local control was 100% at 11.4 months median follow-up. Twelve meningioma patients with median PTV of 5.5 cc (range 0.68-22.3) received 17-30 Gy in 1-5 fractions: 83% experienced no acute toxicity, 33% reported no late toxicity, 88% of symptoms were stable/improved and local control was 100% at 22.1 months median follow-up. Seven patients with other tumor types with median PTV of 24.3 cc (range 7.6-100.5) received 15-28.5 Gy in 1-5 fractions: 57% experienced no acute toxicity, 57% reported no late toxicities, 66% of symptoms were stable and local control was 43% at 14.9 months median follow-up. When tumor types were considered together, smaller tumors (PTV < 6.4 cc) showed reduced acute toxicity (p = 0.01). Overall, smaller benign tumors showed low acute toxicity, excellent local control, and good symptom management: a focus on enhanced neurological preservation may refine outcomes. For other tumor types outcome was encouraging: a focus on optimal dose and fractionation scheduling may reduce toxicity and improve local control. Individual patient experiences are detailed where valuable lessons were gained for optimizing local control and minimizing toxicity.
- 1 April 2016
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 26 (2) , 149-156
Dose-Volume Histogram Analysis of Stereotactic Body Radiotherapy Treatment of Pancreatic Cancer: A Focus on Duodenal Dose Constraints
- 1 April 2016
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 26 (2) , 149-156
Dose-Volume Histogram Analysis of Stereotactic Body Radiotherapy Treatment of Pancreatic Cancer: A Focus on Duodenal Dose Constraints
- Open Access
- 1 January 2012
- Published by E-MED LTD in Cancer Imaging
- Vol. 12 (2) , 351-360
Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
Stereotactic ablative body radiotherapy (SABR) represents a technological breakthrough in radiotherapy technique, with proven benefits to patients in terms of improved tumour control and overall survival. The key components of SABR are described. ...
- 1 January 2012
- Published by E-MED LTD in Cancer Imaging
- Vol. 12 (2) , 351-360
Open AccessStereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
Stereotactic ablative body radiotherapy (SABR) represents a technological breakthrough in radiotherapy technique, with proven benefits to patients in terms of improved tumour control and overall survival. The key components of SABR are described. ...